CVS Health Corp To Distribute New Diabetic Nutrition Beverage From Glucose Health, Inc.

It’s no secret the global pandemic is creating unprecedented market volatility. Companies racing for a vaccine like Moderna and Inovio have seen their market valuations soar and then fall with every new headline. However, a number of companies focused on developing innovative new drug and nutrition products for obesity and diabetes, which are both linked to the pandemic, are also benefitting from the increased market interest – and likely have more staying power. Here are the key companies in the sector with important news this week. Pfizer Inc. (NYSE: PFE), Amarin Corporation (NASDAQ AMRN) Esperion Therapeutics Inc. (NASDAQ: ESPR) Amyris Inc. (NASDAQ: AMRS) and Glucose Health, Inc. (OTC: GLUC)

Glucose Health, Inc. (OTC: GLUC) BREAKING NEWS: Glucose Health, Inc. Glucose Health, Inc. (OTC: GLUC) today confirmed that CVS HEALTH CORP – the nation’s largest pharmacy retailer – has agreed to distribute the Company’s innovative beverage for the adult-diabetic nutrition retail category, GLUCODOWN®.

Murray Fleming, CEO of Glucose Health, Inc., stated, “CVS is embarking on a significant corporate expansion of diabetic care at many of its pharmacies nationwide and we are very pleased GLUCODOWN® has been included given the important role nutrition can play in this initiative”.

Many clinical studies underpin the efficacy of the principal nutritional ingredient in GLUCODOWN®. Clinical data generated from this research was submitted to the Food & Drug Administration (FDA) by the ingredient manufacturer, resulting last year in favorable revision to FDA regulations and industry guidance with regard to the labeling of products utilizing the ingredient, including GLUCODOWN®.

CVS is a leader among pharmacy retailers in mandating independent third-party testing using the ANSI 173 standard – the only American National Standard for testing and certifying dietary supplements, maintained by NSF International. Random samples of GLUCODOWN® were provided to NSF International and the successful test results were released simultaneously to CVS and Glucose Health, Inc., on May 5, 2020.

Other related developments from around the markets include:

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 1:20 p.m. EDT. To listen to the webcast, visit our web site at

Amarin Corporation (NASDAQ AMRN) announced that it intends to increase the level and breadth of its promotion and education initiatives regarding VASCEPA® (icosapent ethyl). As early signs emerge of patients returning to physicians’ offices, Amarin plans to emphasize its key marketing messages including positioning VASCEPA as the only FDA-approved drug for lowering the persistent cardiovascular risk beyond statin therapy for millions of high-risk patients. While VASCEPA has been developed and clinically tested for over a decade, it was less than six months ago (December 2019) that the FDA approved VASCEPA for its unique cardiovascular risk reduction indication. Most healthcare professionals and at-risk patients are unaware that VASCEPA is the first and only drug with this important new indication. For this reason, and the emerging return of patients, Amarin believes the opportunity exists for increasing awareness of VASCEPA and its potential to provide an important healthcare solution to reduce cardiovascular risk in high-risk patients.

Esperion Therapeutics Inc. (NASDAQ: ESPR) reported financial results for the first quarter ended March 31, 2020, which included the first-ever product sales revenue for NEXLETOL™ tablets, and provided other company updates. “With two marketing approvals in the U.S. and two in the E.U., the commercial launch of NEXLETOL™ tablets in the U.S. by our highly-tenured customer-facing team, completion of a second precedent-setting ex-U.S. collaboration, and achievement of our ambitious managed care coverage goals in the U.S., our Esperion team continues to excel,” said Tim M. Mayleben, president and chief executive officer of Esperion. “These accomplishments showcase the potential of our Lipid Management business over the long term as we continue to deliver upon commitments to patients, healthcare providers, our managed care partners, shareholders, and other stakeholders.”

Amyris Inc. (NASDAQ: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients announced the launch of “Baby Cream to Powder” under its Pipette™ baby brand giving caring parents more choice and keeping babies safe. This safe, talc-free alternative to baby powder goes on as an easy-to-apply cream to prevent and treat diaper rash and irritation and transforms into a silky powder on skin, eliminating the risk of powder inhalation. The announcement by Amyris comes on the heels of news that the largest and leading provider of baby care products will stop selling talcum-based baby powder in the U.S. and Canada amidst questions about its product safety.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Glucose Health Inc has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Glucose Health Inc. Please click here for full disclaimer.

Contact Information: